Boehringer Ingelheim logoBoehringer Ingelheim

Family-owned German pharma and the largest private GLP-1 challenger, anchored by survodutide for obesity and MASH

Ingelheim am Rhein, Germany~54,500 (group)Founded 1885Privately held (not publicly traded) raisedwww.boehringer-ingelheim.com
IndustriesGLP-1

Market Metrics

Net Sales (2024)

€26.8B

+6% (currency-adjusted)

Human Pharma Sales (2024)

€21.9B

Animal Health Sales (2024)

€4.7B

R&D Investment (2024)

€6.2B

23.2% of net sales

Employees

~54,500

Ownership

100% family-owned

Lead GLP-1 Asset

Survodutide (Ph3)

Up to 16.6% weight loss (SYNCHRONIZE-1)

Funding History

Total raised: Privately held (not publicly traded)

RoundDateAmountValuationKey Investors

Product Specifications

AssetMechanismStageIndicationsNotes
Survodutide (BI 456906)GLP-1 / glucagon dual agonistPhase 3Obesity, MASHLead metabolic asset, licensed from and co-developed with Zealand Pharma. SYNCHRONIZE-1 reported up to 16.6% weight loss at 76 weeks (Apr 2026). LIVERAGE (MASH) program ongoing
Jardiance (empagliflozin)SGLT2 inhibitorMarketedType 2 diabetes, heart failure, CKDCardio-renal-metabolic franchise, marketed in alliance with Eli Lilly
Ofev (nintedanib)Tyrosine kinase inhibitorMarketedIdiopathic pulmonary fibrosis, ILDLeading anti-fibrotic franchise

Partnerships & Investors

Zealand PharmaLicensing / Co-Development

Survodutide originated from Zealand Pharma; Boehringer leads global development and commercialization, with milestone and royalty payments to Zealand

Eli LillyStrategic Alliance

Diabetes alliance (since 2011) underpinning the Jardiance franchise

Key Milestones

1885

Company Founded

Albert Boehringer establishes the business in Ingelheim am Rhein, Germany

2011

Diabetes Alliance with Eli Lilly

Forms a global diabetes alliance with Eli Lilly to jointly develop and commercialize a portfolio of diabetes compounds; Jardiance is the significant product family in the collaboration

Nov 2023

SYNCHRONIZE Phase 3 Obesity Program Starts

Starts the survodutide SYNCHRONIZE Phase 3 program in people with overweight or obesity: SYNCHRONIZE-CVOT on 20 Nov 2023, SYNCHRONIZE-1 on 25 Nov 2023 and SYNCHRONIZE-2 on 27 Nov 2023

Oct 2024

Survodutide Breakthrough Therapy (MASH)

Survodutide (GLP-1/glucagon dual agonist) receives FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis, announced in October 2024 together with the start of the LIVERAGE Phase 3 trials

Apr 2026

SYNCHRONIZE-1 Obesity Results

In people with overweight or obesity without type 2 diabetes, survodutide delivers up to 16.6% weight loss at 76 weeks versus 3.2% on placebo (efficacy estimand)

KPI data tables

Boehringer Ingelheim operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Boehringer Ingelheim R&D Spend: Human Pharma + Animal Health (Annual) (EUR millions)
PeriodHuman Pharma R&D (other therapy areas)Obesity + cardiometabolic (survodutide, est.)Animal Health R&D
20245,350350500
20234,950250600
20224,400180420
20213,500130450
20203,15090460

Source: Boehringer Ingelheim annual reports (boehringer-ingelheim.com; published annually for the prior calendar year); Human Pharma + Animal Health R&D split disclosed in the financial review. Reported group/Human-Pharma R&D: 2024 ~EUR 6.2B group / ~EUR 5.7B Human Pharma; 2023 ~EUR 5.8B / ~EUR 5.2B; 2022 ~EUR 5.0B group. The Human-Pharma + Animal-Health totals match reported figures; the obesity/cardiometabolic sub-allocation is estimate-driven because BI does not disclose therapy-area-level R&D budgets.

Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership) (EUR millions)
PeriodCumulative BI payments to Zealand (EUR millions, estimated)
2024150
2023140
2022110
202095
201555
201141

Source: Zealand Pharma annual + interim reports (counterparty disclosure of payments received from the Boehringer partnership); original 2011 partnership announcement (lead candidate ZP2929); disclosed milestone receipts (~EUR 20M in 2020, ~EUR 30M in 2023). The cumulative curve is estimate-driven and anchored to these disclosed milestones (Zealand aggregates partner revenue rather than itemizing a BI-specific cumulative figure), so intermediate-year values are approximate.

Frequently asked questions

What does Boehringer Ingelheim do?

Largest private GLP-1 player. Survodutide (dual GLP-1/glucagon, Phase 3 with Zealand) with MASH and obesity readouts expected 2026 to 2027. Family-owned German pharma. Boehringer Ingelheim was founded in 1885, is headquartered in Ingelheim am Rhein, Germany and employs ~54,500 (group).

How much funding has Boehringer Ingelheim raised?

Boehringer Ingelheim has raised Privately held (not publicly traded) in total, based on the funding rounds Sterling tracks.

Who are Boehringer Ingelheim's main competitors?

Sterling groups Boehringer Ingelheim in the GLP-1 industry, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).

If I'm investing in Boehringer Ingelheim, what similar companies should I consider?

If you are researching Boehringer Ingelheim, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 industry on Sterling.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites